Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review.
Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review.
复制标题
DOI：
10.1016/j.fertnstert.2013.01.147
复制
发表时间：
2013-06
影响因子：
6.7
通讯作者：
Venkatesan, Aradhana M.
中科院分区：
文献类型：
--
作者：
Lewis, Erin I.;Chason, Rebecca J.;DeCherney, Alan H.;Armstrong, Alicia;Elkas, John;Venkatesan, Aradhana M.
关键词：
评价新型激素疗法在不可切除的良性转移性平滑肌瘤（BML）疾病患者中的应用。案例系列。美国国立卫生研究院（NIH）。5例受试者根据影像学和/或组织病理学诊断诊断为BML。4例患者接受醋酸亮丙瑞林和/或芳香酶抑制剂单药或联合治疗。1例患者接受了抗白蛋白（CDB-2914）治疗。采用RECIST（实体瘤疗效评价标准）1.1指南，通过横截面成像上的肿瘤负荷测量对治疗的反应。4例接受醋酸亮丙瑞林和/或芳香酶抑制剂单药或联合治疗的患者显示疾病稳定，肿瘤负荷降低。第五位接受抗肿瘤素（CDB-2914）治疗的患者肿瘤退化，肿瘤大小增加，症状改善。促性腺激素释放激素激动和/或芳香化酶抑制激素治疗可能是一种治疗选择，以减少不可切除的BML疾病的肿瘤负荷或那些希望避免手术干预的患者。RECIST 1.1指南虽然传统上用于评价肿瘤对癌症治疗的反应，但可能有助于评价BML肿瘤负荷对激素治疗的反应。
To evaluate novel hormonal therapies in patients with unresectable Benign Metastasizing Leiomyoma (BML) disease. Case series. National Institutes of Health (NIH). 5 subjects with the diagnosis of BML based on imaging and/or histopathologic diagnosis. Four patients were treated with single or combination therapy of Leuprolide acetate and/or an aromatase inhibitor. One patient was treated with an antiprogestin (CDB-2914). Response to therapy was measured by tumor burden on cross-sectional imaging employing RECIST (Response Evaluation Criteria in Solid Tumours) 1.1 guidelines. Four patients treated with single or combination therapy of Leuprolide acetate and/or an aromatase inhibitor demonstrated stable disease with reduction in tumor burden. The fifth patient treated with antiprogestin (CDB-2914) had degeneration of her tumor, progression of its size and an improvement in symptoms. Hormonal treatment with GnRH agonism and/or aromatase inhibition may be a therapeutic option to reduce tumor burden in unresectable BML disease or for those patients who wish to avoid surgical intervention. RECIST 1.1 guidelines, while traditionally used to evaluate tumor response to cancer therapeutics, may be useful in evaluating BML tumor burden response to hormonal therapy.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.1111/j.1471-0528.1986.tb08043.x
发表时间：
1986-06-01
期刊：
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
影响因子：
--
作者：
EVANS, AJ;WILTSHAW, E;SEARS, RT
通讯作者：
SEARS, RT
影响因子：
2.6
作者：
Egberts, Jan-Hendrik;Schafmayer, Clemens;Tepel, Juergen
通讯作者：
Tepel, Juergen
影响因子：
3.3
作者：
CHO, KR;WOODRUFF, JD;EPSTEIN, JI
通讯作者：
EPSTEIN, JI
DOI：
10.1111/j.1525-1438.2006.00607.x
发表时间：
2006-05-01
影响因子：
4.8
作者：
Arif, S.;Ganesan, R.;Spooner, D.
通讯作者：
Spooner, D.